Microglia, Calcification and Neurodegenerative Diseases

Neurodegeneration is a complex process involving different cell types andneurotransmitters. A common characteristic of neurodegenerative disorders such asAlzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis, Huntington’s disease (HD) and Amyotrophic Lateral Sclerosis (ALS) is the occurrence of a neuroinflammatoryreaction in which cellular processes involving glial cells (mainly microglia and astrocytes) and T cells are activated in response to neuronal death. This inflammatory reaction has recently received attention as an unexpected potential target for the treatment of these diseases.Microglial cells have a mesenchymal origin, invade the central nervous system (CNS)prenatally (Chan et al., 2007b) and are the resident macrophages in the CNS (Ransohoff &Perry, 2009). They comprise approximately 10-20% of adult glia and serve as the CNS innateimmune system. In neurodegenerative diseases, microglia is activated by misfoldedproteins. In the case of AD, amyloid- (A ) peptides accumulate extracellularly and activate the microglia locally. In the case of PD, ALS and HD, the misfolded proteins accumulate intracellularly but are still associated with activation of the microglia (Perry et al., 2010). Reactive microglia in the substantia nigra and striatum of PD brains have been described, and increased levels of proinflammatory cytokines and inducible nitric oxide synthase havebeen detected in these brain regions, providing evidence of a local inflammatory reaction (Hirsch & Hunot, 2009). The injection of lipopolysaccharide (a potent microglia activator) into the substantia nigra produces microglial activation and the death of dopaminergic cells. These findings support the hypothesis that microglial activation and neuroinflammationcontribute to PD pathogenesis (Herrera et al., 2000)...

Multislice CT for assessing in-stent dimensions after left main coronary artery stenting: a comparison with three dimensional intravascular ultrasound

Objective: To evaluate the agreement between multislice CT (MSCT) and intravascular ultrasound (IVUS) to assess the in-stent lumen diameters and lumen areas of left main coronary artery (LMCA) stents. Design: Prospective, observational single centre study. Setting: A single tertiary referral centre. Patients: Consecutive patients with LMCA stenting excluding patients with atrial fibrillation and chronic renal failure. Interventions: MSCT and IVUS imaging at 912 months follow-up were performed for all patients. Main outcome measures: Agreement between MSCT and IVUS minimum luminal area (MLA) and minimum luminal diameter (MLD). A receiver operating characteristic (ROC) curve was plotted to find the MSCT cut-off point to diagnose binary restenosis equivalent to 6 mm2 by IVUS. Results: 52 patients were analysed. PassingBablok regression analysis obtained a β coefficient of 0.786 (0.586 to 1.071) for MLA and 1.250 (0.936 to 1.667) for MLD, ruling out proportional bias. The α coefficient was −3.588 (−8.686 to −0.178) for MLA and −1.713 (−3.583 to −0.257) for MLD, indicating an underestimation trend of MSCT. The ROC curve identified an MLA ≤4.7 mm2 as the best threshold to assess in-stent restenosis by MSCT. Conclusions: Agreement between MSCT and IVUS to assess in-stent MLA and MLD for LMCA stenting is good. An MLA of 4.7 mm2 by MSCT is the best threshold to assess binary restenosis. MSCT imaging can be considered in selected patients to assess LMCA in-stent restenosis

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

Background: Vorapaxar is a new oral protease-activatedreceptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. Methods: In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization. RESULTS: Follow-up in the trial was terminated early after a safety review. After a median follow-up of 502 days (interquartile range, 349 to 667), the primary end point occurred in 1031 of 6473 patients receiving vorapaxar versus 1102 of 6471 patients receiving placebo (KaplanMeier 2-year rate, 18.5% vs. 19.9%; hazard ratio, 0.92; 95% confidence interval [CI], 0.85 to 1.01; P = 0.07). A composite of death from cardiovascular causes, myocardial infarction, or stroke occurred in 822 patients in the vorapaxar group versus 910 in the placebo group (14.7% and 16.4%, respectively; hazard ratio, 0.89; 95% CI, 0.81 to 0.98; P = 0.02). Rates of moderate and severe bleeding were 7.2% in the vorapaxar group and 5.2% in the placebo group (hazard ratio, 1.35; 95% CI, 1.16 to 1.58; P<0.001). Intracranial hemorrhage rates were 1.1% and 0.2%, respectively (hazard ratio, 3.39; 95% CI, 1.78 to 6.45; P<0.001). Rates of nonhemorrhagic adverse events were similar in the two groups. Conclusions: In patients with acute coronary syndromes, the addition of vorapaxar to standard therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage. (Funded by Merck; TRACER ClinicalTrials.gov number, NCT00527943.)

Cardiac motion estimation by joint alignment of tagged MRI sequences

Image registration has been proposed as an automatic method for recovering cardiac displacement fields from Tagged Magnetic Resonance Imaging (tMRI) sequences. Initially performed as a set of pairwise registrations, these techniques have evolved to the use of 3D+t deformation models, requiring metrics of joint image alignment (JA). However, only linear combinations of cost functions defined with respect to the first frame have been used. In this paper, we have applied k-Nearest Neighbors Graphs (kNNG) estimators of the -entropy (H ) to measure the joint similarity between frames, and to combine the information provided by different cardiac views in an unified metric. Experiments performed on six subjects showed a significantly higher accuracy (p < 0.05) with respect to a standard pairwise alignment (PA) approach in terms of mean positional error and variance with respect to manually placed landmarks. The developed method was used to study strains in patients with myocardial infarction, showing a consistency between strain, infarction location, and coronary occlusion. This paper also presentsan interesting clinical application of graph-based metric estimators, showing their value for solving practical problems found in medical imaging.

Papillary cystoadenoma lymphomatosum (Warthin-like) of minor salivary glands

Papillary cystadenoma lymphomatosum is a benign salivary gland tumor most frequently located in the parotid gland (Warthin"s tumor). Its presentation in other major, or in minor, salivary glands is rare. Clinically, it manifests as a slow growing tumor, fluctuant on palpation due to its cystic morphology. The treatment of choice is complete excision with wide tumor-free margins. We present a 73-year-old female patient with an asymptomatic tumor of 8 years evolution in the right posterior area of the hard palate. We performed surgical excision and a biopsy, which was reported as papillary cystadenoma lymphomatosum. During the post-operative examination carried out after 3 weeks, it was observed that the lesion had recurred. The lesion was re-operated, performing the excision with CO2 laser and including the periosteum to ensure complete resection of the tumor. At 10 months follow-up, there was no recurrence of the lesion. This article includes a review of this condition and discusses its most important clinical and pathologic features and therapeutic approaches.

L'alimentació humana del Paleolític Superior al Neolític. Canvis i efectes de la Revolució Neolítica en la salut

Dieta Flash, Dieta Dukan, Dieta Mediterrània, Dieta Vegetariana o Dieta Paleolítica són només alguns exemples de les setanta-dos diferents dietes que es practiquen en l’actualitat (Dukan, 2011). Tanmateix, tot i convergir a l’hora d’autoproclamer-se com a baluard d’una “forma de vida sana” que portarà als seus seguidors a la “felicitat” i a evitar les anomenades “malalties de la civilització”1 (Milton, 2000; Cordain, 2011; Pérez, 2012; Campos, 2012), alhora, el tret comú de totes aquestes dietes és la manca de quòrum –àdhuc posicions antagòniques− en llur concepció del que hauria de ser una “dieta sana”.

Depression-like behavior is dependent on age in male SAMP8 mice

Aging is associated with an increased risk of depression in humans. To elucidate the underlying mechanisms of depression and its dependence on aging, here we study signs of depression in male SAMP8 mice. For this purpose, we used the forced swimming test (FST). The total floating time in the FST was greater in SAMP8 than in SAMR1 mice at 9 months of age; however, this difference was not observed in 12-month-old mice, when both strains are considered elderly. Of the two strains, only the SAMP8 animals responded to imipramine treatment. We also applied the dexamethasone suppression test (DST) and studied changes in the dopamine and serotonin (5-HT) uptake systems, the 5-HT2a/2c receptor density in the cortex, and levels of TPH2. The DST showed a significant difference between SAMR1 and SAMP8 mice at old age. SAMP8 exhibits an increase in 5-HT transporter density, with slight changes in 5-HT2a/2c receptor density. In conclusion, SAMP8 mice presented depression-like behavior that is dependent on senescence process, because it differs from SAMR1, senescence resistant strain.

Dietary resveratrol prevents alzheimer's markers and increases life span in SAMP8

Resveratrol is a polyphenol that is mainly found in grapes and red wine and has been reported to be a caloric restriction (CR) mimetic driven by Sirtuin 1 (SIRT1) activation. Resveratrol increases metabolic rate, insulin sensitivity, mitochondrial biogenesis and physical endurance, and reduces fat accumulation in mice. In addition, resveratrol may be a powerful agent to prevent age-associated neurodegeneration and to improve cognitive deficits in Alzheimer's disease (AD). Moreover, different findings support the view that longevity in mice could be promoted by CR. In this study, we examined the role of dietary resveratrol in SAMP8 mice, a model of age-related AD. We found that resveratrol supplements increased mean life expectancy and maximal life span in SAMP8 and in their control, the related strain SAMR1. In addition, we examined the resveratrol-mediated neuroprotective effects on several specific hallmarks of AD. We found that long-term dietary resveratrol activates AMPK pathways and pro-survival routes such as SIRT1 in vivo. It also reduces cognitive impairment and has a neuroprotective role, decreasing the amyloid burden and reducing tau hyperphosphorylation.

Susceptibility to exacerbation in chronic obstructive pulmonary disease

Background Although we know that exacerbations are key events in chronic obstructive pulmonary disease (COPD), our understanding of their frequency, determinants, and effects is incomplete. In a large observational cohort, we tested the hypothesis that there is a frequent-exacerbation phenotype of COPD that is independent of disease severity. Methods We analyzed the frequency and associations of exacerbation in 2138 patients enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate End points (ECLIPSE) study. Exacerbations were defined as events that led a care provider to prescribe antibiotics or corticosteroids (or both)or that led to hospitalization (severe exacerbations). Exacerbation frequency was observed over a period of 3 years. Results Exacerbations became more frequent (and more severe) as the severity of COPD increased; exacerbation rates in the first year of follow-up were 0.85 per person for patients with stage 2 COPD (with stage defined in accordance with Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages), 1.34 for patients with stage 3, and 2.00 for patients with stage 4. Overall, 22% of patients with stage 2 disease, 33% with stage 3, and 47% with stage 4 had frequent exacerbations (two or more in the first year of follow-up). The single best predictor of exacerbations, across all GOLD stages, was a history of exacerbations. The frequent-exacerbation phenotype appeared to be relatively stable over a period of 3 years and could be predicted on the basis of the patient"s recall of previous treated events. In addition to its association with more severe disease and prior exacerbations, the phenotype was independently associated with a history of gastroesophageal reflux or heartburn, poorer quality of life, and elevated white-cell count. Conclusions Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype. This has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity. (Funded by GlaxoSmithKline; ClinicalTrials .gov number, NCT00292552.)

Dietary resveratrol prevents alzheimer's markers and increases life span in SAMP8

Resveratrol is a polyphenol that is mainly found in grapes and red wine and has been reported to be a caloric restriction (CR) mimetic driven by Sirtuin 1 (SIRT1) activation. Resveratrol increases metabolic rate, insulin sensitivity, mitochondrial biogenesis and physical endurance, and reduces fat accumulation in mice. In addition, resveratrol may be a powerful agent to prevent age-associated neurodegeneration and to improve cognitive deficits in Alzheimer's disease (AD). Moreover, different findings support the view that longevity in mice could be promoted by CR. In this study, we examined the role of dietary resveratrol in SAMP8 mice, a model of age-related AD. We found that resveratrol supplements increased mean life expectancy and maximal life span in SAMP8 and in their control, the related strain SAMR1. In addition, we examined the resveratrol-mediated neuroprotective effects on several specific hallmarks of AD. We found that long-term dietary resveratrol activates AMPK pathways and pro-survival routes such as SIRT1 in vivo. It also reduces cognitive impairment and has a neuroprotective role, decreasing the amyloid burden and reducing tau hyperphosphorylation.

La valoració prehospitalària del dolor en el pacient politraumatitzat: una nova eina per valorar i enregistrar el dolor

Els pacients politraumatitzats representen un important problema a nivell mundial i també en el nostre país. Els traumatismes són una important causa de mortalitat per a la població més jove i provoquen unes seqüeles molt importants, tant a nivell físic, psicològic i social. Un dels factors que influeixen en l’aparició d’aquestes seqüeles és el dolor que pateixen aquests malalts durant els moments posteriors a l’accident. És per aquest motiu que al llarg d’aquest treball de final de carrera d’infermeria, s’intentarà donar una solució útil per als professionals sanitaris encarregats d’atendre aquests pacients en primera instància. En primer lloc és farà una descripció d’alguns dels temes més importants i més destacats pel que fa als pacients politraumatitzats i al dolor que aquests pateixen. A continuació es donaran a conèixer algunes dades pel que fa a la prevalença d’aquest problema i per últim es presentarà una nova eina de valoració del dolor pensada per donar solució als problemes que els professionals sanitaris tenen de resoldre durant la seva practica clínica diària. En el present treball també es té en compte de quina forma es realitzarà una avaluació dels resultats de la mateixa eina per tal d’estudiar els seus punts més dèbils i implantar noves mesures enfocades a millorar-ne el funcionament.

Disseny d'un programa educatiu per prevenir les complicacions associades a l'alteració del perfil lipídic durant la gestació

L’embaràs és una situació especial en la vida de la dona que condiciona canvis en la seva fisiologia i en el desenvolupament d’un nou ésser. Entre aquests canvis fisiològics trobem l’augment dels nivells de colesterol i triglicèrids degut, majoritàriament, a l’augment de les hormones sexuals esteroidees i al metabolisme hepàtic i adipós alterat. Ara bé, cal mantenir aquests nivells dins d’uns límits per tal que no esdevinguin factor de risc de malalties futures, tant en la dona gestant com en el futur nadó.

Formació sanitària al cuidador informal en les cures del pacient pal·liatiu al domicili

En els últims anys s’ha produït un augment progressiu de la incidència i la prevalença de les malalties cròniques evolutives, i com a conseqüència de la mortalitat. Tot això està directament relacionat amb l’envelliment de la població que fa que a la vegada, s’incrementi el nombre de malalts crònics amb un deteriorament físic progressiu i amb grans necessitats d’atenció i de cures físiques, psicològiques, socials i espirituals. Aquest canvi en les necessitats requereix del desenvolupament de noves fórmules d’atenció i organització.

Protocol pel correcte manteniment de la via subcutànea en cures pal·liatives aplicades a domicili

La medicina al llarg de la història ha anat evolucionant a mesura que també ho anava fent la societat. És per això que en el darrer segle existeix una medicina que no està orientada a la curació de la patologia, sinó que tracta d’aconseguir la major qualitat de vida del pacient ancià o jove, amb patologies cròniques, en estadi de final de la malaltia i també en pacients oncològics i no oncològics, és a dir, s’intenta prestar una atenció sanitària, no curativa, als que tenen una malaltia avançada, progressiva i incurable que precisen una sèrie d’intervencions que no només es basen en procediments mèdics, sinó també en socials i psicològics. És per la necessitat que la medicina s’adaptés a les demandes de la societat que al 1990 es crea a Catalunya el Pla de Cures Pal·liatives de Catalunya com a programa pilot de l’Organització Mundial de la Salut (OMS). Aquest programa ha esdevingut tot un referent de les cures pal·liatives (CP) a España, és el Programa d’Atenció Domiciliària i Equips de Suport (PADES) on un equip interdisciplinari (metge, infermer, treballador social, fisioterapeuta i psicòleg) treballen per tenir una cura holística del pacient al seu domicili. Així, doncs, l’objectiu del PADES és alleugerir el patiment i millorar, tant com es pugui, la qualitat de vida i acompanyar-los en el procés de mort al seu domicili.

Estressors i ansietat en els cuidatges pal·liatius: Una proposta de canvi en el pla d'estudis d'Infermeria

Néixer, créixer, madurar, envellir i morir, són les etapes que travessa l’ésser humà al llarg de la seva vida, però no necessàriament s’ha d’envellir per arribar a la mort. Hi ha persones que la vida biològica s’acaba abans de la mort. Són els pacients terminals. Per tenir cura dels malalts al final de la seva vida, s’implanten els cuidatges pal·liatius. A partir d’aquests cuidatges, es proporciona una atenció global, activa i continuada als pacients i als seus familiars, amb l’objectiu de millorar la qualitat de vida i cobrir totes les necessitats d’aquests pacients.